Cholangiocarcinoma (CCA) and its subtypes (mucin-and mixed-CCA) arise from the neoplastic transformation of cholangiocytes, the epithelial cells lining the biliary tree. CCA has a high mortality rate owing to its aggressiveness, late diagnosis and high resistance to radiotherapy and chemotherapeutics. We have demonstrated that CCA is enriched for cancer stem cells which express epithelial to mesenchymal transition (EMT) traits, with these features being associated with aggressiveness and drug resistance. TGF-beta signaling is upregulated in CCA and involved in EMT. We have recently established primary cell cultures from human mucin-and mixed-intrahepatic CCA. In human CCA primary cultures with different levels of EMT trait expression, we evaluated the anticancer effects of: (i) CX-4945, a casein kinase-2 (CK2) inhibitor that blocks TGF-beta 1-induced EMT; and (ii) LY2157299, a TGF-beta receptor I kinase inhibitor. We tested primary cell lines expressing EMT trait markers (vimentin, N-cadherin and nuclear catenin) but negative for epithelial markers, and cell lines expressing epithelial markers (CK19-positive) in association with EMT traits. Cell viability was evaluated by MTS assays, apoptosis by Annexin V FITC and cell migration by wound-healing assay. Results: at a dose of 10 mu M, CX4945 significantly decreased cell viability of primary human cell cultures from both mucin and mixed CCA, whereas in CK19-positive cell cultures, the effect of CX4945 on cell viability required higher concentrations (>30 mu M). At the same concentrations, CX4945 also induced apoptosis (3-fold increase vs controls) which correlated with the expression level of CK2 in the different CCA cell lines (mucin-and mixed-CCA). Indeed, no apoptotic effects were observed in CK19-positive cells expressing lower CK2 levels. The effects of CX4945 on viability and apoptosis were associated with an increased number of gamma-H2ax (biomarker for DNA double-strand breaks) foci, suggesting the active role of CK2 as a repair mechanism in CCAs. LY2157299 failed to influence cell proliferation or apoptosis but significantly inhibited cell migration. At a 50 mu M concentration, in fact, LY2157299 significantly impaired (at 24, 48 and 120 hrs) the wound-healing of primary cell cultures from both mucin-and mixed-CCA. In conclusion, we demonstrated that CX4945 and LY2157299 exert relevant but distinct anticancer effects against human CCA cells, with CX4945 acting on cell viability and apoptosis, and LY2157299 impairing cell migration. These results suggest that targeting the TGF-beta signaling with a combination of CX-4945 and LY2157299 could have potential benefits in the treatment of human CCA.
TGF-β signaling is an effective target to impair survival and induce apoptosis of human cholangiocarcinoma cells: a study on human primary cell cultures / Lustri, Anna Maria; Di Matteo, Sabina; Fraveto, Alice; Costantini, Daniele; Cantafora, Alfredo; Napoletano, Chiara; Bragazzi, Maria Consiglia; Giuliante, Felice; De Rose, Agostino M; Berloco, Pasquale B; Grazi, Gian Luca; Carpino, Guido; Alvaro, Domenico. - In: PLOS ONE. - ISSN 1932-6203. - 12:9(2017), pp. 1-18. [10.1371/journal.pone.0183932]
TGF-β signaling is an effective target to impair survival and induce apoptosis of human cholangiocarcinoma cells: a study on human primary cell cultures
Napoletano, Chiara;Bragazzi, Maria Consiglia;Berloco, Pasquale B;Carpino, Guido;Alvaro, Domenico
2017
Abstract
Cholangiocarcinoma (CCA) and its subtypes (mucin-and mixed-CCA) arise from the neoplastic transformation of cholangiocytes, the epithelial cells lining the biliary tree. CCA has a high mortality rate owing to its aggressiveness, late diagnosis and high resistance to radiotherapy and chemotherapeutics. We have demonstrated that CCA is enriched for cancer stem cells which express epithelial to mesenchymal transition (EMT) traits, with these features being associated with aggressiveness and drug resistance. TGF-beta signaling is upregulated in CCA and involved in EMT. We have recently established primary cell cultures from human mucin-and mixed-intrahepatic CCA. In human CCA primary cultures with different levels of EMT trait expression, we evaluated the anticancer effects of: (i) CX-4945, a casein kinase-2 (CK2) inhibitor that blocks TGF-beta 1-induced EMT; and (ii) LY2157299, a TGF-beta receptor I kinase inhibitor. We tested primary cell lines expressing EMT trait markers (vimentin, N-cadherin and nuclear catenin) but negative for epithelial markers, and cell lines expressing epithelial markers (CK19-positive) in association with EMT traits. Cell viability was evaluated by MTS assays, apoptosis by Annexin V FITC and cell migration by wound-healing assay. Results: at a dose of 10 mu M, CX4945 significantly decreased cell viability of primary human cell cultures from both mucin and mixed CCA, whereas in CK19-positive cell cultures, the effect of CX4945 on cell viability required higher concentrations (>30 mu M). At the same concentrations, CX4945 also induced apoptosis (3-fold increase vs controls) which correlated with the expression level of CK2 in the different CCA cell lines (mucin-and mixed-CCA). Indeed, no apoptotic effects were observed in CK19-positive cells expressing lower CK2 levels. The effects of CX4945 on viability and apoptosis were associated with an increased number of gamma-H2ax (biomarker for DNA double-strand breaks) foci, suggesting the active role of CK2 as a repair mechanism in CCAs. LY2157299 failed to influence cell proliferation or apoptosis but significantly inhibited cell migration. At a 50 mu M concentration, in fact, LY2157299 significantly impaired (at 24, 48 and 120 hrs) the wound-healing of primary cell cultures from both mucin-and mixed-CCA. In conclusion, we demonstrated that CX4945 and LY2157299 exert relevant but distinct anticancer effects against human CCA cells, with CX4945 acting on cell viability and apoptosis, and LY2157299 impairing cell migration. These results suggest that targeting the TGF-beta signaling with a combination of CX-4945 and LY2157299 could have potential benefits in the treatment of human CCA.File | Dimensione | Formato | |
---|---|---|---|
Lustri_TGF-β-signaling_2017.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
641.56 kB
Formato
Adobe PDF
|
641.56 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.